Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release.

Kevin Dang Giulia CastelloStarlynn C ClarkeYuping LiAarti BalasubramaniAndrew BoudreauLaura DavisonKatherine E HarrisDuy PhamPreethi SankaranHarshad S UgamrajRong DengSerena KwekAlec StarzinskiSuhasini IyerWim van SchootenUte SchellenbergerWenchao SunNathan D TrinkleinRoland BuelowBen BuelowLawrence FongPranjali Dalvi

Published in: Journal for immunotherapy of cancer (2021)

Our data suggest that TNB-585, with its low-affinity anti-CD3, may be efficacious while inducing a lower incidence and severity of CRS in patients with prostate cancer compared with TCEs that incorporate high-affinity anti-CD3 domains.

Keyphrases

prostate cancer
radical prostatectomy
nk cells
risk factors
electronic health record
big data
deep learning
artificial intelligence
benign prostatic hyperplasia
capillary electrophoresis